BioClock: Bright Light Therapy for Depressive Disorders

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversiteit Leiden

About this trial

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response.

This clinical trial has three main goals:

* Optimize the administration of BLT for patients with depressive episodes. * Gain a deeper understanding of the treatment mechanisms. * Determine which patients benefit the most from the treatment.

The specific objectives are as follows:

* Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT. * Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes. * Identify patient characteristics and behaviours that can predict treatment outcomes. * Develop a brain model to better understand the impact of BLT on the brain.

In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups:

* Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands. * LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day. * LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light.

The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 65.

Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) as assessed with the Mini-International Neuropsychiatric Interview (M.I.N.I.)

A current depressive episode (a score of 6 or higher on the Quick Inventory of depressive symptomatology Self Report (QIDS-SR)

Sufficient knowledge of Dutch or English language to fill in questionnaires

Disqualifiers

A current (hypo)manic or mixed episode (as assessed with the M.I.N.I.)

Current psychotic episode (as assessed with the M.I.N.I.)

Prominent active suicidality (score 10 or higher on the M.I.N.I. module)

Antidepressant therapy (medication, psychotherapy or BLT, or other forms of specific treatments for depression) that started less than 2 months prior to study entry

Trial design

Design model

Parallel

Treatments tested in this trial

  • Bright Light Therapy

    Procedure/Surgery

    In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).

  • Blue Light Blocking Glasses

    Device

    Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.

Treatment groups

231 Participants
are divided into 3 treatment groups
Group A: Light@HomeActive comparator 1 intervention
Group B: LightCaféExperimental treatment 1 intervention
Group C: LightCafé+Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Clinical Improvement

Difference between pre- and post-treatment assessment of the Montgomery Asberg Depression Rating Scale \[MADRS\]

Time frame
2-5 weeks

Secondary outcomes

1

Subjective change in depressive symptom severity

Change in score on the Quick Inventory of Depressive Symptoms, Self Report (QIDS-SR)

Time frame
from baseline until follow-up, approximately 4 months
2

Remission rates, self assessed and clinician rated

percentage of patients that after treatment have a score of \<6 on the MADRS or QIDS-SR

Time frame
2-5 weeks for clinician rated. Up until 4 months after start treatment for self-assessed
3

Response Rates, self assessed and clinician rated

percentage of patients hat after treatment have at least 50% reduction in depressive symptom, measured using MADRS and QIDS-SR

Time frame
2-5 weeks for clinician rated, Up until 4 months after start treatment for self-assessed
4

Time to remission

The time it takes to achieve remission, if remission is achieved. Measured with QIDS-SR

Time frame
one, two or three weeks

Other outcomes

1

Personal daily light exposure

the percentage of time exposed to light above the threshold of 300 lux will be calculated from light sensor data as well as the mean timing thereof (MLiT100). Additional parameter might be extracted from the light exposure data based on state of the art procedures.

Time frame
2-5 weeks
2

Treatment expectations

Treatment expectations will be assessed using the Credibility/expectancy Questionnaire

Time frame
baseline
3

Light Induced Melatonin suppression

Light Induced Melatonin suppression as assessed using the salivary melatonin assessments will give insight into light sensitivity of the participants.

Time frame
Baseline
4

Treatment Adherence

Treatment adherence will be assessed subjectively using an item in the EMA and objectively using light logger devices.

Time frame
1-3 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universiteit Leiden

Lead sponsor

Eindhoven University of Technology

Collaborator

Geestelijke Gezondheidszorg Eindhoven (GGzE)

Collaborator

Chrono@Work B.V.

Collaborator